Fisher Asset Management
CLDX icon

Fisher Asset Management’s Celldex Therapeutics CLDX Stock Holding History

Fisher Asset Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$36.7M Sell
985,677
-27,971
-3% -$903K 0.01% 275
2026
Q1 		$32.2M Buy
1,013,648
+76,490
+8% +$2.09M 0.01% 279
2025
Q4 		$25.5M Buy
937,158
+10,001
+1% +$263K 0.01% 295
2025
Q3 		$24M Buy
927,157
+104,949
+13% +$2.43M 0.01% 301
2025
Q2 		$16.7M Sell
822,208
-49,420
-6% -$962K 0.01% 343
2025
Q1 		$15.8M Buy
871,628
+419,131
+93% +$9.36M 0.01% 353
2024
Q4 		$11.4M Buy
452,497
+78,145
+21% +$2.12M ﹤0.01% 416
2024
Q3 		$12.7M Buy
374,352
+253,808
+211% +$9.67M 0.01% 389
2024
Q2 		$4.46M Sell
120,544
-3,292
-3% -$124K ﹤0.01% 498
2024
Q1 		$5.2M Buy
123,836
+102,024
+468% +$4.19M ﹤0.01% 502
2023
Q4 		$865K Buy
21,812
+1,274
+6% +$37.5K ﹤0.01% 710
2023
Q3 		$565K Hold
20,538
– – ﹤0.01% 835
2023
Q2 		$697K Hold
20,538
– – ﹤0.01% 833
2023
Q1 		$739K Sell
20,538
-8,479
-29% -$366K ﹤0.01% 806
2022
Q4 		$1.29M Sell
29,017
-4,876
-14% -$174K ﹤0.01% 723
2022
Q3 		$953K Buy
+33,893
New +$1.04M ﹤0.01% 680

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fisher Asset Management's CLDX Position: Q2 2026 in Review

Fisher Asset Management reduced its Celldex Therapeutics (CLDX) stake by 2.8% in Q2 2026, selling an estimated $903K and leaving 985,677 shares worth $36.7M. The position accounts for 0.01% of the portfolio, ranked #275.

Fisher Asset Management first reported a position in CLDX in Q3 2022 and has held it in 16 quarters since. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • Fisher Asset Management held 985,677 shares of Celldex Therapeutics worth $36.7M as of Q2 2026.
  • Fisher Asset Management sold 27,971 Celldex Therapeutics shares in Q2 2026, an estimated $903K.
  • Celldex Therapeutics made up 0.01% of Fisher Asset Management's portfolio in Q2 2026, its #275 holding.
  • Fisher Asset Management first reported a position in Celldex Therapeutics in Q3 2022 and has held it in 16 quarters since.
  • 253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Fisher Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.